Form 4: Nektar R&D Chief Sells Shares Under 10b5-1 Plan

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 1,721 shares of common stock on September 4, 2025, through a pre-arranged 10b5-1 trading plan.

Summary

• Jonathan Zalevsky, Chief R&D Officer of Nektar Therapeutics (NKTR), reported the sale of common stock.
• The transactions occurred on September 4, 2025, and were executed under a Rule 10b5-1 trading plan.
• A total of 1,721 shares of common stock were sold across four separate transactions.
• The sales were conducted at weighted average prices ranging from $32.43 to $35.69 per share.
• Following these reported transactions, Jonathan Zalevsky beneficially owns 17,462 shares of Nektar Therapeutics common stock.

Sentiment

Score: 4

Explanation: The filing reports insider selling by a key executive, which can be perceived negatively by the market, although the transactions were conducted under a pre-arranged 10b5-1 trading plan, mitigating some of the negative sentiment.

Negatives

• The Chief R&D Officer, a key executive, sold a total of 1,721 shares of common stock.
• Insider selling, even when pre-planned, can sometimes be interpreted by the market as a signal of reduced confidence or a move to diversify holdings.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially influencing investor sentiment and the company's stock price.

Key Dates

Recommendation

The sale by the Chief R&D Officer, while executed under a pre-arranged 10b5-1 plan, could introduce some negative sentiment. However, without further context on the company's performance or other market factors, a 'hold' recommendation is appropriate as this single transaction does not fundamentally alter the investment thesis. Investors should monitor future insider activity and company developments.

Keywords

Nektar Therapeutics, NKTR, Insider Trading, Form 4, Stock Sale, Jonathan Zalevsky, Chief R&D Officer, 10b5-1 plan